Lim Jonathan E — SEC Form 4 filings
SEC reporting owner CIK 1283290. 12 Form 4 filings on record with FilingPulse; latest filed 2026-06-15.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2024-02-07 to 2026-06-15. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 21.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | Director | 3 | — | — | 9 |
| Boundless Bio, Inc. (BOLD) | Director | 5 | — | — | 8 |
| Erasca, Inc. (ERAS) | Chairman & CEO, Director, 10% owner | 4 | — | — | 4 |
Form 4 filings — Lim Jonathan E
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-15 | 4 | Boundless Bio, Inc. (BOLD) | Grant/award (A): 48,000 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Maze Therapeutics, Inc. (MAZE) | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2026-01-30 | 4 | Erasca, Inc. (ERAS) | Grant/award (A): 2,000,000 (derivative) @ $0 | EDGAR |
| 2025-09-24 | 4 | Maze Therapeutics, Inc. (MAZE) | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | Boundless Bio, Inc. (BOLD) | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2025-02-05 | 4 | Erasca, Inc. (ERAS) | Grant/award (A): 2,500,000 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Maze Therapeutics, Inc. (MAZE) | Conversion (C): 37,724 · Conversion (C): 270,232 · Conversion (C): 363,703 (derivative) · Conversion (C): 2,231,381 (derivative) · Grant/award (A): 5,704 (derivative) · Disposition to issuer (D): 5,704 (derivative) · +1 more | EDGAR |
| 2024-06-21 | 4 | Erasca, Inc. (ERAS) | Grant/award (A): 632,759 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Boundless Bio, Inc. (BOLD) | Grant/award (A): 6,610 (derivative) @ $0 | EDGAR |
| 2024-04-04 | 4 | Boundless Bio, Inc. (BOLD) | Conversion (C): 525,274 · Conversion (C): 512,820 (derivative) · Conversion (C): 5,128 (derivative) · Conversion (C): 7,326 (derivative) | EDGAR |
| 2024-03-29 | 4 | Boundless Bio, Inc. (BOLD) | Grant/award (A): 13,219 (derivative) @ $0 | EDGAR |
| 2024-02-07 | 4 | Erasca, Inc. (ERAS) | Grant/award (A): 1,500,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1283290 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →